Efficacy and Safety of Thermobalancing Therapy in Men with Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia was Confirmed by Clinical Trial
Abstract
Background: Lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) is the most common problem for men older than age 50, and in men older than 80 the prevalence from this disorder reaches 90%. Benign tumor, by pressing the bladder and the urethra, causes LUTS that interfere men’s quality of life. The aim of this 2.5-year investigation to find out if Thermobalancing therapy is effective and safe to treat LUTS/BPH Methods: 124 men older than 55 with LUTS and the prostate volume (PV) up to 60 mL received Thermobalancing therapy enabled by therapeutic device during 6 months. Before and after treatment were investigated the International Prostate Symptom Score (IPSS), including quality of life (QoL) index, ultrasound measurement of PV and uroflowmetry maximum flow rate (Qmax). Also, before and after 7-month therapy the dynamics of the same parameters were studied in men with BPH and PV > 60 mL. Results: After treatment the dynamics of clinical parameters in 124 men with PV 60 mL have shown positive results: the PV level reduced (P <0.001), increased Qmax (P <0.001), improved QoL and diminished IPSS (P <0.001). The dynamics of the same measurements in the control-group who did not receive treatment have shown negative outcomes. Conclusions: The observed positive effect of therapeutic device, termed Dr Allen’s Device, for BPH has allowed us to recommend Thermobalancing therapy as a new safe physiotherapeutic solution for men with enlarged prostate. However, require…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.